1. patients who have received treatment with plasma from covid-19 convalescents. 2. patients who are participating in other therapeutic clinical trials 3. patients who require mechanical respiratory assistance or are hospitalized in the icu at the time of the screening visit. 4. history of anaphylaxis, prior administration of equine serum (por example, anti-tetanus serum or anti-ophidic serum or anti-arachnid toxin serum) or allergic reaction due to contact or exposure to horses. 5. pregnant or breastfeeding women 6. patients who, at the doctor's discretion, are likely to die within the next 30 days due to a concomitant disease other than the study disease 7. patients who are expected to be referred to another institution within 72 hours of enrollment, which prevents proper follow-up of that patient.

1. patients who have received treatment with plasma from covid-19 convalescents. 2. patients who are participating in other therapeutic clinical trials 3. patients who require mechanical respiratory assistance or are hospitalized in the icu at the time of the screening visit. 4. history of anaphylaxis, prior administration of equine serum (por example, anti-tetanus serum or anti-ophidic serum or anti-arachnid toxin serum) or allergic reaction due to contact or exposure to horses. 5. pregnant or breastfeeding women 6. patients who, at the doctor's discretion, are likely to die within the next 30 days due to a concomitant disease other than the study disease 7. patients who are expected to be referred to another institution within 72 hours of enrollment, which prevents proper follow-up of that patient.

patients who have received treatment with plasma from covid-19 convalescents. patients who are participating in other therapeutic clinical trials patients who require mechanical respiratory assistance or are hospitalized in the icu at the time of the screening visit. history of anaphylaxis, prior administration of equine serum (por example, anti-tetanus serum or anti-ophidic serum or anti-arachnid toxin serum) or allergic reaction due to contact or exposure to horses. pregnant or breastfeeding women patients who, at the doctor's discretion, are likely to die within the next 30 days due to a concomitant disease other than the study disease patients who are expected to be referred to another institution within 72 hours of enrollment, which prevents proper follow-up of that patient.

patients who have received treatment with plasma from covid-19 convalescents. patients who are participating in other therapeutic clinical trials patients who require mechanical respiratory assistance or are hospitalized in the icu at the time of the screening visit. history of anaphylaxis, prior administration of equine serum (por example, anti-tetanus serum or anti-ophidic serum or anti-arachnid toxin serum) or allergic reaction due to contact or exposure to horses. pregnant or breastfeeding women patients who, at the doctor's discretion, are likely to die within the next 30 days due to a concomitant disease other than the study disease patients who are expected to be referred to another institution within 72 hours of enrollment, which prevents proper follow-up of that patient.

1. patients who have received treatment with plasma from covid-19 convalescents. 2. patients who are participating in other therapeutic clinical trials 3. patients who require mechanical respiratory assistance or are hospitalized in the icu at the time of the screening visit. 4. history of anaphylaxis, prior administration of equine serum (por example, anti-tetanus serum or anti-ophidic serum or anti-arachnid toxin serum) or allergic reaction due to contact or exposure to horses. 5. pregnant or breastfeeding women 6. patients who, at the doctor's discretion, are likely to die within the next 30 days due to a concomitant disease other than the study disease 7. patients who are expected to be referred to another institution within 72 hours of enrollment, which prevents proper follow-up of that patient.

1. patients who have received treatment with plasma from covid-19 convalescents. 2. patients who are participating in other therapeutic clinical trials 3. patients who require mechanical respiratory assistance or are hospitalized in the icu at the time of the screening visit. 4. history of anaphylaxis, prior administration of equine serum (por example, anti-tetanus serum or anti-ophidic serum or anti-arachnid toxin serum) or allergic reaction due to contact or exposure to horses. 5. pregnant or breastfeeding women 6. patients who, at the doctor's discretion, are likely to die within the next 30 days due to a concomitant disease other than the study disease 7. patients who are expected to be referred to another institution within 72 hours of enrollment, which prevents proper follow-up of that patient.